MGMartin Geyer

Martin Geyer

*This is an algorithmically generated author record based on publicly available information.

Martin Geyer has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Carbon Dioxide Insufflation in Colonoscopy Is Safe: A Prospective Trial of 347 Patients

    by M. Geyer, U. Guller, Ch. Beglinger

    Available evidence suggests that the use of CO2 insufflation in endoscopy is more comfortable for the patient. The safety of CO2 use in colonoscopy remains contentious, particularly in sedated patients. The objective of the present prospective trial was to assess the safety of CO2 colonoscopies. Methods. 109 patients from our previous randomized CO2 colonoscopy study and an additional 238 subsequent consecutive unselected patients who had a routine colonoscopy performed in a private practice were enrolled from April 2008 through September 2008. All but 2 patients were sedated. All patients were routinely monitored with transcutaneous CO2 measurement. Volumes of CO2 administered were correlated with capnographic measurements from transcutaneous monitoring. Results. Of the 347 patients examined, 57% were women; mean (SD) age of participants was of 60.2 years (12.8). Mean propofol dosage was 136 mg (64 mg). Mean CO2 values were 34.7 mm Hg (5.3) at baseline, 38.9 mm Hg (5.5) upon reaching the ileum, and 36.9 mm Hg (5.0) at examination's end. Mean maximum increase of CO2 was 4.5 mm Hg (3.6). No correlation was observed between volume of CO2 administered and increase in level of CO2 (correlation coefficient: 0.01; P value: 0.84). No complications were observed. Conclusions. The present prospective study, which was based on one of the largest sedated patient sample reported to date in this setting, provides compelling evidence that CO2 insufflation in colonoscopy is safe and unassociated with relevant increases in transcutaneously measured levels of CO2.


  • Open Access

    Carbon Dioxide Insufflation in Routine Colonoscopy Is Safe and More Comfortable: Results of a Randomized Controlled Double-Blinded Trial

    by M. Geyer, U. Guller, C. Beglinger

    Many patients experience pain and discomfort after colonoscopy. Carbon dioxide (CO2) can reduce periprocedural pain although air insufflation remained the standard procedure. The objective of this double-blinded, randomized controlled trial was to evaluate whether CO2 insufflation does decrease pain and bloating during and after colonoscopy compared to room air. Methods. 219 consecutive patients undergoing colonoscopy were randomized to either CO2 or air insufflation. Propofol was used in all patients for sedation. Transcutaneous CO2 was continuously measured with a capnograph as a safety parameter. Pain, bloating, and overall satisfaction were assessed at regular intervals before and after the procedure. Results(data are mean ±SD). 110 patients were randomized to CO2 and 109 to room air. The baseline characteristics were similar in both groups. The mean propofol dose was not different between the treatments, as were the time to reach the ileum and the withdrawal time. pCO2 at the end of the procedure was mmHg (CO2 group) versus mmHg in the room air group (). No relevant complication occurred in either group. There was significantly less bloating for the CO2 group during the postprocedural recovery period () and over the 24-hour period (). Also, patients with CO2 insufflation experienced significantly less pain (). Finally, a higher overall satisfaction ( ) was found in the CO2 group. Conclusions. This trial provides compelling evidence that CO2 insufflation significantly reduces bloating and pain after routine colonoscopy in propofol-sedated patients. The procedure is safe with no significant differences in CO2 between the two groups.


  • Effect of Yacon (Smallanthus sonchifolius) on Colonic Transit Time in Healthy Volunteers

    by M. Geyer, I. Manrique, L. Degen, C. Beglinger

    Background: Yacon is a root crop which contains high amounts of fructooligosaccharides (FOS). The aim of this study was to investigate the effects of yacon syrup on colon transit time in healthy volunteers. Methods: In a placebo-controlled, double-blind study yacon was administered to 16 healthy individuals (8 males, 8 females) in a dose of 20 g daily (equal to 6.4 g FOS) in a 2-week crossover design. Each period was interrupted by a 2-week wash-out phase. Transit time was assessed by a radio-opaque marker technique. Results: Transit time (mean ± SEM) through the gastrointestinal tract was significantly decreased from 59.7 ± 4.3 to 38.4 ± 4.2 h (p < 0.001). Yacon was well tolerated with an excellent side effect profile. Bloating is not an uncommon side effect observed with FOS, but bloating-related disturbances were not significantly more often reported with yacon compared to placebo. Stool frequency increased from 1.1 ± 0.1 to 1.3 ± 0.2 times per day and the consistency showed a tendency for softer stools as assessed by a numerical depicted stool protocol. Neither parameter did, however, reach statistical significance. Conclusion: Yacon markedly accelerates colonic transit in healthy individuals. Further studies are needed in constipated patients to confirm these preliminary data. Due to the low caloric content of yacon, the root could be a useful treatment in constipated diabetics or obese patients.


    • 10 March 2007
      • Vol. 137, 146-50

    Application of bleeding prophylactic criteria (NICE) in patients with acute gastrointestinal bleeding. A Swiss prospective study.

    by Martin Geyer, Shajan Peter, Hugo Bühler, Philipp Bertschinger

    Multiple treatment guidelines for nonsteroidal anti-inflammatory drugs (NSAIDs) suggest that patients with one or more risk factors for NSAID-related ulcer complications should be prescribed preventive strategies such as acid-suppressive drugs, misoprostol or COX-2-specific inhibitors to reduce their risk of serious ulcer complications. However data are lacking as to how many patients have been on preventive measures in accordance to the National Institute for Clinical Excellence (NICE) criteria in our population. We therefore evaluated the extent to which patients with acute gastrointestinal bleeding have been under ulcer-preventive strategies at the time of hospital entry. In a one-year-bleeding-study at the Waid city hospital, Zürich, ulcer preventive treatment was practiced in only 25% of 214 patients with acute gastrointestinal bleeding. We conclude that ulcer prevention in everyday medical practice is still being seldom applied.

    • 19 August 2006
      • Vol. 136, 544-7

    Serum immunoglobin G4 (IgG4): an important marker in autoimmune pancreatitis?

    by Michael C Sulz, Martin Geyer, Shajan Peter, Lukas Degen

    A unique form of chronic pancreatitis has recently become widely recognised as an important clinical entity in the spectrum of pancreatic diseases under the term autoimmune pancreatitis (AIP). This entity is characterised by irregular narrowing of the pancreatic duct, swelling of parenchyma, lymphoplasmacytic infiltration and fibrosis as well as favourable response to corticosteroid treatment. In addition, increased concentration of serum immunoglobulin G4 (IgG4) is a notable characteristic marker. Some patients undergoing pancreaticoduodenectomy for presumed pancreatic ductal adenocarcinoma have instead been found to have AIP. Early recognition of AIP can prevent pancreaticoduodenectomy in these patients and effective treatment with steroids can be introduced. Based on an interesting case, we discuss the entity of AIP with the rare combination of sclerosing cholangitis and we focus on the relevance of serum IgG4 as a factor in diagnosis and monitoring therapy of AIP.

  • Epidemiologie gastrointestinaler Blutungen bei älteren Patienten

    by M Geyer, I Stamenic, H Bühler, P Bertschinger

    In westlichen Ländern steigt der Anteil an alten, polymorbiden Patienten stetig. Inwieweit diese Tatsache die Manifestationsformen der Gastrointestinalblutungen (GIB) beeinflusst, wurde im Rahmen dieser prospektiven Studie am Stadtspital Waid während eines Jahres untersucht. Bei 7406 konsekutiv hospitalisierten Patienten wurden insgesamt 224 GIB registriert (53% Frauen; mittleres Alter 71 ± 16 Jahre, 63% mit relevanter Komorbidität). Von den 197 abgeklärten Patienten litten 51% an einer oberen GIB (OGIB), 37% an einer unteren GIB (UGIB), und 2% hatten sowohl eine OGIB wie auch UGIB. In 10% der Fälle blieb die Ursache unklar. Folgende Blutungsquellen wurden gefunden: Ulcera ventriculi und/oder duodeni 24%; Kolondivertikel 16%; Kolitiden 10%; Ösophagitiden 10%; Mallory-Weiss-Läsionen 6%; Varia 24%. Die Häufigkeit der GIB nahm mit zunehmendem Patientenalter signifikant zu (p < 0.001), insbesondere die Divertikelblutung, welche signifikant mit der Acetylsalicylsäure (ASS)-Einnahme assoziiert war. Die Prognose der Gastrointestinalblutungen war auch bei betagten Patienten mit einer blutungsassoziierten Mortalität von 3.1% insgesamt günstig.